Hemostatic and Anti-Inflammatory Effects of Carbazochrome Sodium Sulfonate in Patients Undergoing Total Knee Arthroplasty: A Randomized Controlled Trial |
| |
| Institution: | 1. Orthopaedic and Trauma Unit, University of Pisa, Pisa, Italy;2. BEAMS Department (Bio Electro and Mechanical Systems), Université Libre de Bruxelles, Brussels, Belgium;1. Department of Trauma and Orthopaedic Surgery, North Hampshire Hospital (Hampshire Hospitals NHS Trust), Basingstoke, Hampshire, United Kingdom;2. Department of Orthopaedic and Trauma Surgery, Central Finland Central Hospital, Jyvaskyla, Finland;3. Department of Orthopaedic and Trauma Surgery, Kymenlaakso Central Hospital, Kotka, Finland;1. School of Medicine, Pharmacy and Health, Durham University, Stockton, United Kingdom;2. Trauma and Orthopaedics, Northumbria Healthcare NHS Foundation Trust, Northumberland, United Kingdom;3. Princess Elizabeth Orthopaedic Centre, Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom;4. Trauma and Orthopaedics, Guys and St Thomas’ Hospital, London, United Kingdom;5. Trauma and Orthopaedics, South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom;6. Health Sciences, University of York, York, United Kingdom;1. Adult Reconstruction and Joint Replacement Division, Hospital for Special Surgery, New York, NY;2. Department of Orthopedics, Vienna General Hospital, Medical University of Vienna, Vienna, Austria |
| |
| Abstract: | BackgroundPostoperative recovery after total knee arthroplasty (TKA) is associated with postoperative anemia, allogeneic transfusion, and stress immune responses to surgery. Carbazochrome sodium sulfonate (CSS) reduces bleeding through several mechanisms. We assessed the effect of CSS combined with tranexamic acid (TXA) on postoperative anemia, blood transfusion, and inflammatory responses.MethodsThis study was designed as a randomized, placebo-controlled trial of 200 patients undergoing unilateral primary TKA. Patients were divided into 4 groups: group A received TXA plus topical and intravenous CSS; group B received TXA plus topical CSS only; group C received TXA plus intravenous CSS only; group D received TXA only.ResultsTotal blood loss in groups A (609.92 ± 221.24 mL), B (753.16 ± 247.67 mL), and C (829.23 ± 297.45 mL) was lower than in group D (1158.26 ± 334.13 mL, P < .05). There was no difference in total blood loss between groups B and C. We also found that compared with group D, the postoperative swelling rate, biomarker level of inflammation, visual analog scale pain score, and range of motion at discharge in groups A, B, and C were significantly improved (P < .05). No thromboembolic complications occurred. There were no differences in transfusion rate, intraoperative blood loss, platelet count, or average length of stay among the 4 groups (P > .05).ConclusionCSS combined with TXA was more effective than TXA alone in reducing perioperative blood loss and inflammatory response and did not increase the incidence of thromboembolism complications. |
| |
| Keywords: | blood loss inflammation carbazochrome sodium sulfonate tranexamic acid total knee arthroplasty |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
